References
- Nunes ML, Tabarin A. Les actualités de l'insuffisance
surrénalienne. Ann Endocrinol. 2008; 69: S44-52. PubMed | Google
Scholar
- Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien
DE, Svartberg J et al. Clinical, immunological, and genetic features
of autoimmune primary adrenal insufficiency: observations from a Norwegian
registry. J Clin Endocrinol Metab. 2009; 94(12): 4882-90. PubMed | Google
Scholar
- Menon S, Kuhn J-M. Insuffisance surrénalienne. Encycl
Med Chir (Elsevier Masson, Paris Endocrinologie-Nutrition). 2011; 10-015-A-10.
In press.
- Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope
A, Hammer GD et al. Diagnosis and treatment of primary adrenal insufficiency:
an endocrine society clinical practice guideline. J Clin Endocrinol Metab.
2016; 101(2): 364-89. PubMed | Google
Scholar
- Falorni A, Minarelli V, Morelli S. Therapy of adrenal
insufficiency: an update. Endocrine. 2013; 43(3): 514-28. PubMed | Google
Scholar
- Oksnes M, Ross R, Løvås K. Optimal glucocorticoid replacement
in adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2015; 29(1):
3-15. PubMed | Google
Scholar
- Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson
G. Premature Mortality in Patients with Addison's Disease: a Population-Based
Study. J Clin Endocrinol Metab. 2006; 91(12): 4849-53. PubMed | Google
Scholar
- Aulinas A, Casanueva F, Goñi F, Monereo S, Moreno B, Picó A et
al. Adrenal insufficiency and adrenal replacement therapy: current status
in Spain. Endocrinol Nutr. 2013; 60(3): 136-43. PubMed | Google
Scholar
- Leelarathna L, Breen L, Powrie JK, Thomas SM, Guzder R,
McGowan B et al. Co-morbidities, management and clinical outcome of
auto-immune Addison's disease. Endocrine. 2010; 38(1): 113-7. PubMed | Google
Scholar
- Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson
A, Johannsson G. The impact of glucocorticoid replacement regimens on metabolic
outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab.
2006; 91(10): 3954-61. PubMed | Google
Scholar
- Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P,
Dahlqvist P, Ekman B et al. Improved cortisol exposure-time profile
and outcome in patients with adrenal insufficiency: a prospective randomized
trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol
Metab. 2012;97(2): 473-81. PubMed | Google
Scholar
- Giordano R, Marzotti S, Balbo M, Romagnoli S, Marinazzo
E, Berardelli R et al. Metabolic and cardiovascular profile in patients
with Addison's disease under conventional glucocorticoid replacement. J Endocrinol
Invest. 2009; 32(11): 917-23. PubMed | Google
Scholar
- Carr MC. The emergence of the metabolic syndrome with
menopause. J Clin Endocrinol Metab. 2003; 88(6): 2404-11. PubMed | Google
Scholar
- Alonso N, Granada ML, Lucas A, Salinas I, Reverter J,
Oriol A et al. Evaluation of two replacement regimens in primary adrenal
insufficiency patients: effect on clinical symptoms, health-related quality
of life and biochemical parameters. J Endocrinol Invest. 2004; 27(5): 449-54. PubMed | Google
Scholar
- Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price
J, Doane A, Ibbotson V et al. Weight-related dosing, timing and monitoring
hydrocortisone replacement therapy in patients with adrenal insufficiency.
Clin Endocrinol (Oxf). 2004; 61(3): 367-75. PubMed | Google
Scholar
- Løvås K, Husebye ES. High prevalence and increasing incidence
of Addison's disease in western Norway. Clin Endocrinol (Oxf). 2002; 56(6):
787-91. PubMed | Google
Scholar
- Andersson DKG, Svärdsudd K, Tibblin G. Prevalence and
Incidence of Diabetes in a Swedish Community 1972-1987. Diabet Med. 1991; 8(5):
428-34. PubMed | Google
Scholar
- Debono M, Ross RJ, Newell-Price J. Inadequacies of glucocorticoid
replacement and improvements by physiological circadian therapy. Eur J Endocrinol.
2009; 160(5): 719-29. PubMed | Google
Scholar
- Plat L, Byrne MM, Sturis J, Polonsky KS, Mockel J, Féry
F et al. Effects of morning cortisol elevation on insulin secretion
and glucose regulation in humans. Am J Physiol. 1996; 270: E36-42. PubMed | Google
Scholar
- Heureux F, Maiter D, Boutsen Y, Devogelaer JP, Jamart
J, Donckier J. Évaluation de la substitution par corticostéroïdes et de ses
répercussions osseuses dans la maladie d'Addison. EM consulte. 2006; 61(3):
179-83. PubMed | Google
Scholar
- Hazra A, Pyszczynski NA, DuBois DC, Almon RR, Jusko WJ.
Modeling of corticosteroid effects on hepatic low-density lipoprotein receptors
and plasma lipid dynamics in rats. Pharm Res. 2008; 25(4): 769-80. PubMed | Google
Scholar
- Nanjee MN, Miller NE. Plasma lipoproteins and adrenocortical
hormones in men-positive association of low density lipoprotein cholesterol
with plasma cortisol concentration. Clin Chim Acta. 1989; 180(2): 113-20. PubMed | Google
Scholar
- Ross IL, Bergthorsdottir R, Levitt N, Dave JA, Schatz
D, Marais D et al. Cardiovascular risk factors in patients with Addison's
disease: a comparative study of South African and Swedish patients. PLoS One.
2014; 9(3): 1-6. PubMed | Google
Scholar
- Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan
A. Correction of cortisol overreplacement ameliorates morbidities in patients
with hypopituitarism: a pilot study. Rev Argent Endocrinol Metab. 2009; 46(2):
25-34. PubMed | Google
Scholar
- Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum
EM, Huppert FA et al. Long-term DHEA replacement in primary adrenal
insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab. 2008;
93(2): 400-9. PubMed | Google
Scholar
- Ross IL, Bergthorsdottir R, Levitt NS, Schatz DA, Johannsson
G, Marais AD. Increased cardiovascular risk in South African patients with
addison's disease. Horm Metab Res. 2013; 45(12): 905-10. PubMed | Google
Scholar
- Ettinger WH, Hazzard WR. Prednisone increases very low
density lipoprotein and high density lipoprotein in healthy men. Metabolism.
1988; 37(11): 1055-8. PubMed | Google
Scholar
- Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP. Decreased
plasma cholesterol esterification and cholesteryl ester transfer in hypopituitary
patients on glucocorticoid replacement therapy. Scand J Clin Lab Invest. 2000;
60(3): 189-98. PubMed | Google
Scholar
- Van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol
transport during inflammation. Curr Opin Lipidol. 2007; 18(2): 147-51. PubMed | Google
Scholar
- Quinkler M, Hahner S. What is the best long-term management
strategy for patients with primary adrenal insufficiency? Clin Endocrinol
(Oxf). 2012; 76(1): 21-5. PubMed | Google
Scholar
- Devogelaer JP, Crabbé J, Nagant de Deuxchaisnes C. Bone
mineral density in Addison's disease: evidence for an effect of adrenal androgens
on bone mass. Br Med J (Clin Res Ed). 1987; 294(6575): 798-800. PubMed | Google
Scholar
- Bensing S, Brandt L, Tabaroj F, Sjöberg O, Nilsson B, Ekbom A et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf). 2008; 69(5):697-704. PubMed | Google Scholar
- Wei L, MacDonald TM, Walker BR. Taking glucocorticoids
by prescription is associated with subsequent cardiovascular disease. Ann Intern
Med. 2004; 141(10): 764-70. PubMed | Google
Scholar
- McFarlane SI, Sowers JR. Cardiovascular endocrinology
1: aldosterone function in diabetes mellitus: effects on cardiovascular and
renal disease. J Clin Endocrinol Metab. 2003; 88(2): 516-23. PubMed | Google
Scholar